RxDoctor Payments Data

Joseph Vassallo, MD

Cardiovascular Disease · Chevy Chase, MDNPI 1932106846

Payments from drug & device makers

$11,085in general payments, 2019–2025

Across 488 payments — averaging $22.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Pfizer$1K
  • Boehringer Ingelheim$988
  • Novartis$929
  • Johnson & Johnson$887
  • E.r. Squibb & Sons, L.L.C.$861
  • plus $5K from 43 others

What the payments were for

  • Food & beverage$10,95699%
  • Education$1291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,085 in reported general payments places this provider in the 80th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$692,139
Medicare patients
1,249
Services billed
7,426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban486$678,709
XareltoRivaroxaban113$167,501
MultaqDronedarone Hcl49$107,110
EntrestoSacubitril/Valsartan64$91,362
Repatha SureclickEvolocumab28$43,059
JardianceEmpagliflozin19$27,989
EdarbyclorAzilsartan Med/Chlorthalidone17$11,799
Metoprolol Succinate659$11,529
Atorvastatin Calcium820$11,192
Nebivolol Hcl117$7,110
Rosuvastatin Calcium304$6,809
Amlodipine Besylate543$4,989
Losartan Potassium369$4,483
Olmesartan Medoxomil156$3,655
Ezetimibe145$3,539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,048$678,709486 claims
Johnson & JohnsonXarelto$887$167,501113 claims
Sanofi-aventis U.S. LLCMultaq$263$107,11049 claims
NovartisEntresto$929$91,36264 claims
Boehringer IngelheimJardiance$988$27,98919 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$38$11,79917 claims
AbbVieSynthroid$22$2,76932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Chevy Chase

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →